Home › Compare › TRKNY vs ABBV
TRKNY yields 68.97% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 6
Combined, TRKNY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRKNY + ABBV for your $10,000?
Türk Telekomünikasyon Anonim Sirketi, together with its subsidiaries, provides integrated telecommunication services in Turkey. The company operates in two segments, Fixed Line and Mobile. It offers mobile, internet, phone and TV products and services under Türk Telekom brand name. The company also provides PSTN and wholesale broadband services; retail internet services, IPTV, satellite TV, Web TV, mobile TV, and smart TV services; IT solutions; convergence technologies; online education software; project development and corporate venture capital services; and wholesale data and capacity services. In addition, it offers TV Broadcasting and VOD services; telecommunications devices sales; payment and e-money services; and web portal and computer programming services. Further, the company provides call center, electric supply and sales, facilities support, and counselling services. As of December 31, 2021, it had 16.9 million fixed access lines; 14.3 million broadband; 2.9 million TV; and 24.0 million mobile subscribers in 81 cities. The company was founded in 1840 and is headquartered in Ankara, Turkey. Türk Telekomünikasyon Anonim Sirketi is a subsidiary of LYY Telekomünikasyon A.S.
Full TRKNY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.